Steven L. Hoerter - 18 Jan 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
President and CEO, Director
Signature
/s/ Thomas P. Kelly, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
18 Jan 2022
Net transactions value
$0
Form type
4
Filing time
20 Jan 2022, 16:00:12 UTC
Previous filing
17 Dec 2021
Next filing
23 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 -415,000 -50% $0.000000 415,000 18 Jan 2022 Common Stock 415,000 $8.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022.